B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients

BACKGROUND: B cells are key players in the pathogenesis of rheumatoid arthritis (RA). Although successful in 50–60% of patients with RA, anti-B-cell therapy given as rituximab could be more efficient by identifying potential responders prior to treatment. Positron emission tomography (PET) using rad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Bruijnen, Stefan, Tsang-A-Sjoe, Michel, Raterman, Hennie, Ramwadhdoebe, Tamara, Vugts, Daniëlle, van Dongen, Guus, Huisman, Marc, Hoekstra, Otto, Tak, Paul-Peter, Voskuyl, Alexandre, van der Laken, Conny
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5116204/
https://ncbi.nlm.nih.gov/pubmed/27863504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1166-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados